Worse OS associated with elevated pre-therapy levels of serum IL-8 was also demonstrated by Schalper et al. [40] in a study involving 1,344 patients with different type of cancer treated with nivolumab or nivolumab plus ipilimumab, among which 887 had melanoma. Here, CXCL8 is linked to cancer.